title: Cerebral protection devices for transcatheter aortic valve implantation: is better the enemy of good?
abstract: Transcatheter aortic valve implantation is a widely performed procedure for treatment of symptomatic severe aortic stenosis. According to the current literature, major stroke has been reported as occurring in 3-6% of patients during the first 30 days following valve implantation. Several pathological mechanisms may be involved in the development of periprocedural ischaemic stroke with the majority being due to thromboembolism and atheroembolism. One approach to reduce the incidence of procedural cerebral thromboembolic events is the use of cerebral protection devices, either deflecting (Embrella, TriGuard) or capturing (Claret, Embol-X) embolic material. We decided to review the current evidence on this important issue focusing on the four cerebral protection devices currently available.
authors.affiliation: Invasive Cardiology, Bern University Hospital, Bern, Switzerland.
authors.forename: Fabien
authors.initials: F
authors.lastname: Praz
authors.forename: Fabian
authors.initials: F
authors.lastname: Nietlispach
mesh_terms: D000497:Alloys; D001021:Aortic Valve; D001024:Aortic Valve Stenosis / Q000628:therapy*; D006328:Cardiac Catheterization / Q000295:instrumentation* / Q000379:methods; D000075202:Contraindications; D004867:Equipment Design; D004864:Equipment and Supplies; D006350:Heart Valve Prosthesis; D019918:Heart Valve Prosthesis Implantation / Q000295:instrumentation* / Q000379:methods; D006801:Humans; D015994:Incidence; D012307:Risk Factors; D020521:Stroke / Q000453:epidemiology / Q000517:prevention & control*; D013923:Thromboembolism / Q000150:complications; D016896:Treatment Outcome
chemical_list: D000497:Alloys; C013616:nitinol